MEDICLIN AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.82 EUR | -1.40% |
|
+4.44% | +2.92% |
| Mar. 27 | MEDICLIN Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 22 | Mediclin to Buy Rehabilitation Clinic in Germany | MT |
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company does not generate enough profits, which is an alarming weak point.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.92% | 145M | - | C | |
| -22.63% | 15.4B | B+ | ||
| +3.60% | 12.12B | B | ||
| +3.65% | 11.43B | B+ | ||
| +11.92% | 10.84B | B+ | ||
| +24.00% | 8.29B | B | ||
| -1.96% | 7.78B | A- | ||
| +20.75% | 7.33B | D | ||
| +4.53% | 6.75B | B- | ||
| +49.97% | 4.65B | - |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings MEDICLIN AG
